An alternative synthesis of Vandetanib (CaprelsaTM) via a microwave accelerated Dimroth rearrangement
View/ Open
Waby_Tetrahedron_Letters (621.3Kb)
Download
Publication date
2017-04-12Rights
©2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).Peer-Reviewed
YesOpen Access status
openAccess
Metadata
Show full item recordAbstract
Vandetanib is an orally available tyrosine kinase inhibitor used in the treatment of cancer. The current synthesis proceeds via an unstable 4-chloroquinazoline, using harsh reagents, in addition to requiring sequential protection and deprotection steps. In the present work, use of the Dimroth rearrangement in the key quinazoline forming step enabled the synthesis of Vandetanib in nine steps (compared to the previously reported 12–14).Version
Published versionCitation
Brocklesby KL, Waby JS, Cawthorne C et al (2017) An alternative synthesis of Vandetanib (CaprelsaTM) via a microwave accelerated Dimroth rearrangement. Tetrahedron Letters. 58(15): 1467-1469.Link to Version of Record
https://doi.org/10.1016/j.tetlet.2017.02.082Type
Articleae974a485f413a2113503eed53cd6c53
https://doi.org/10.1016/j.tetlet.2017.02.082